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 Abstract 
Introduction: A large proportion of prescribed drugs to children is administered orally. Age-
related change in factors affecting oral absorption can have consequences for drug dosing.  
Areas covered: For each process affecting oral drug absorption a systematic search has been 
performed using Medline to identify relevant articles (from inception till February 2012) in 
humans. This review presents the findings on age related changes of the following processes 
affecting oral drug absorption: gastric pH, gastrointestinal motility, bile salts, pancreatic 
function, intestinal pH, intestinal drug metabolizing enzymes and transporter proteins.  
Expert opinion: Clinicians should bear in mind the ontogeny of oral drug absorption processes 
when prescribing oral drugs to children. Our review shows large information gaps on almost 
all drug absorption processes. We present exciting future approaches aimed to reduce these 
gaps: 1. a drug dissolution/solubility intestinal model (TIM) to study differences in oral 
formulations simultaneous with age-related changes. 2. Generation of in vitro data on the 
intestinal ontogeny of drug metabolizing enzymes or transporter proteins. 3. Using these and 
existing data for population and physiology-based pharmacokinetic modeling. 4. (Labeled) 
microdosing studies to determine developmental changes in oral bioavailability in vivo.   
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Article highlights 
- After a peak for the first few minutes postnatally, gastric pH remains around a value of 
2-3 in children of all ages in the unfed state.  
- Gastric emptying in infants appears to be faster than in adults until the age of 3 years.   
- Proximal intestinal (duodenal) motor activity matures throughout the first weeks of 
life, whereas antral motor activity does not. 
- Although there are clear clues of an age-related pattern for some drug metabolizing 
enzymes and transporter proteins in the intestine, the exact ontogeny still remains to 
be elucidated. 
- In vitro studies (tissue drug metabolizing enzymes and transporters), and modeling 
and simulation using TIM, population pharmacokinetic (popPK) or physiology-based 
pharmacokinetic (PBPK) modeling are highly needed to increase our understanding on 
pediatric oral drug absorption. 
- An important challenge is to conduct in vivo research, to validate these study findings, 
for example by using stable isotopes or microdosing to elucidate the ontogeny in oral 
drug absorption and to dose children adequately.  
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1.  Introduction: orally administered drugs in children 
A large proportion of drugs prescribed to children is administered orally [1]. Absorption of 
orally administered drugs may be affected by extrinsic factors (food and formulation) and 
intrinsic factors of a physiological nature. The latter includes volume of gastrointestinal 
fluids, the pH and buffer capacity of these fluids, contraction patterns, gastrointestinal transit, 
digestive enzymes, intestinal cellular transporters, drug metabolism enzymes, and intestinal 
bacterial flora [2]. Solubility and intestinal permeability of the individual drug will influence 
the impact of gastrointestinal (GI) processes on its absorption. A theoretical-based oral drug 
classification based on solubility and permeability characteristics of drugs, such as the 
biopharmaceutics classification system (BCS), may serve to predict which extrinsic or 
intrinsic variables will alter oral drug absorption [2-3]. 
 
As many of the GI processes change with age, oral drug absorption expectedly will change 
with age as well [4]. The current EU and US regulations aimed at stimulating the study of 
drugs across the pediatric age range, have given an impetus to promoting clinical trials in 
children [5-6]. Age-specific information on the processes governing drug disposition in 
children is needed for modelling and simulation approaches. Important progress has been 
made to elucidate age-related changes in drug hepatic drug metabolism and renal excretion [7-
8]. In contrast, our knowledge on developmental changes in the GI processes involved in oral 
drug absorption is far less developed [4, 9-11].  
The aim of this review is to present the available data on age-related variation in GI processes 
that govern oral drug absorption processes. We performed a systematic search in the literature 
using Medline. Reference lists of relevant retrieved papers were screened for additional 
relevant articles. We discuss current information gaps and provide suggestions for future 
research that may lead to develop evidence-based dosing guidelines for oral drugs in children.  
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2.   Age-related changes in oral drug absorption processes 
 
2.1.  Gastric pH 
Gastric pH is an important factor determining the stability of a drug passing through the 
stomach. Studies on gastric pH across the pediatric age range used pH measurement of gastric 
fluid aspirates and 24-hour intragastric pH monitoring [12-29]. Figure 1 displays the mean 
and median gastric pH values in healthy children in the first three months of life.  
The mean gastric pH in newborns minutes after delivery is 7.05 and within a few hours it 
declines to a pH of 2.7 [13, 28]. A less acidic stomach environment in these newborns after 
delivery is most likely explained by swallowing of amnion fluids, which is supported by the 
decrease in pH within a few hours after birth [28].  More than seventy years ago Miller 
observed a decrease in acidity over the first 10 days of life [30]. Many more recent studies 
report that the gastric pH declines already within a few hours after birth [13, 28]. Miller 
titrated gastric juice with NaOH and then determined the amount of HCl as a measure of 
acidity. However, Miller did not provide information on the acidity of the primary gastric 
content; therefore we are unable to translate this outcome to pH. Many other studies 
subsequently showed that the gastric pH remains low at a pH around 2 and 3 in children of all 
ages [12, 14-27, 29]. 
More rarely, gastric pH can be described in terms of the proportion of time it peaks above 4 
measured over 24 hours. In preterm infants, this proportion ranged from 46% to 70% over a 
24-hour period [31-32]. In children up to two years of age it was around 51%; in older 
children it was 34% [33]. The higher proportion in younger children might be explained by 
the buffering effects of milk formula, older children are less frequently fed and receive more 
solid foods [23, 25, 33]. 24h-pH monitoring reflects the buffering effect as well; in preterm 
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infants the gastric pH first increased to 7 postprandially, but then immediately steadily 
declined to a pH of 2 [23]. Another study showed a similar pattern with a mean gastric pH 
returning to a value of 1.8 within 180 minutes postprandially [25]. Apparently, during the day 
younger children tend to have more often a basic gastric environment than older children, 
although the mean gastric pH remains around 2 or 3 in children of all ages.  
Interestingly, this overview gives reason to contradict the widespread notion that absorption 
of gastric pH dependent drugs in both neonates and young infants is affected by high gastric 
pH [34-35]. Gastric pH may be high due to continuous enteral feeds, but is comparable to 
adult values when oral feedings are given at longer than 3 hour intervals. Children older than 
one week of age will typically receive such intermittent feeding, especially during the night. 
We have not been able to identify studies that compared effect of different feeding regimes 
(continuous and intermittent) on drug absorption in neonates. 
The consequences of changes in gastric pH are relevant for acid labile drugs. These may be 
absorbed more efficiently in a higher gastric pH environment achieved by very frequent or 
continuous feeding regimens. Huang et al found that serum penicillin levels in premature and 
term newborns were higher than those in infants and children. These age-related changes were 
hypothesized to be either due to higher gastric pH in the first 10 days of life or to altered renal 
function [36].  
 
2.2.  Gastrointestinal motility 
 
2.2.1.   Gastric emptying 
Next to intestinal motility, gastric emptying is a primary determinant of the rate at which 
drugs are presented to the small intestinal mucosa for absorption. Gastric emptying is usually 
measured by the following methods: gastric emptying breath test, scintigraphic procedure by 
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Technetium-99M liquid gastric emptying scan or the paracetamol absorption test. Gastric 
emptying time is reported in various ways: gastric emptying time, gastric half-emptying time 
or residual gastric activity at 1 hour.  
We identified three studies using the gastric emptying breath tests. Hoekstra et al tested the 
effect of glucose and fructose on gastric emptying using an L-glycine-1-13C breath test in four 
healthy children (mean age 14.3 years; age range 12.1 – 16.0 years). Gastric half emptying 
time after fructose intake was 45.5 minutes (SD 4.9); after glucose intake 64.3 minutes (SD 
2.4). Gastric half emptying time was significantly longer when fructose and glucose were 
administered together, that is 85.3 minutes (SD 7.0) [37].  The authors considered all values 
to be in the normal ranges established with other methods. Using the 13C-octanoic acid breath 
test, Perri et al found a gastric half emptying time of mean 121 minutes (SD 42) in nine 
healthy control patients (mean age 9 years; age range 4-16 years). These children had eaten a 
standard test meal (bread, ham, juice, egg), however, which hardly compares to a smaller 
fructose and/or glucose administration [38]. Hoffman et al subjected 22 patients with 
gastroesophageal reflux symptoms (mean age 13.2 years) to the 13C-octanoic acid breath test 
and compared half emptying results between patients with or without pathologic acid 
exposure (84 (SD 24) vs. 86 (SD 26) minutes) and with or without duodenogastroesophageal 
reflux (105 (SD 47) vs. 76 (SD 24) minutes) were compared. Results were not statistically 
significantly different [39]. In conclusion, breath test measurements for gastric emptying rate 
are highly variable and, probably for practical reasons, that tests have only been performed in 
relatively older children.  
Scintigraphic imaging makes it possible to measure the gastric emptying time or gastric half 
emptying time as well as the residual gastric activity at one hour. We identified seven useful 
scintigraphy studies. In ten preterm infants (median gestational age 28.9 weeks; range 26-33) 
the median gastric half-emptying time at a postnatal median age of 9 days (range 6-37) was 
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60 minutes (30-180 minutes) [40]. Patients were all hourly fed although not receiving a 
standard meal size. The residual gastric activity at one hour was 37.5% (range 19-100%) [40]. 
Di Lorenzo and colleagues conducted a study in 477 patients across a wide age span; 291 
patients with and 186 patients without gastroesophageal reflux disease (GERD) (based on pH 
and/or scintigraphy investigations) [41]. In children without bolus or acidic gastroesophageal 
reflux, gastric residual activity at one hour was around 65% in those up to 3 years of age; it 
decreased to 51% in the age group 4-6 years; and to 45% in children over 6 years of age [41]. 
Seibert et al reported an opposite outcome in children being evaluated for gastroesophageal 
reflux (GER); the percentage emptied at one hour instead of the percentage residual activity 
[42]. The percentage emptied at one hour was 48% (SD 16) in 44 infants (mean age 5.7 
months, range 1-23) and 51% (SD 7) in eight children (mean age 9.1 years, range 2-14.5 
years). When converted to residual gastric activity, values are still comparable (respectively 
52% and 49%). Note that in the study reported by Di Lorenzo et al a delay in gastric emptying 
was not related to GER symptoms until the age of 6 years [41]. Cucchiara et al studied a 
poorly described control group suffering from diarrhoea and failure to thrive not related to 
gastrointestinal symptoms. The gastric emptying activity at one hour was 38.1% (SD 6.5) 
[43]. Miele et al reported a 43.3% (SD 8.7) gastric emptying activity at one hour in a control 
group of 11 children without gastrointestinal or neurologic disorders (mean age 5.6 years; SD 
3.9 years; range 2-12 years) [44]. Describing gastric emptying alternatively as a mean 
emptying half time, Yahav et al reported 87.8 minutes (SD 22.9) mean gastric emptying time 
in a control group with a mean age of 10.4 months for which no other details are reported 
[45]. Demirbilek et al found an average gastric emptying time of 51.6 minutes (SD 8.04) in a 
selected group of children with GERD (mean age 3.2 years; SD 1.1); the selection might have 
resulted in bias [46]. 
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To relate these results to adults, reported healthy adult gastric emptying times range between 
56 (32- 85) and 104 (49-126) minutes, for liquid and solid markers respectively [47-48].  
Finally, the paracetamol absorption test was used in two small cohorts. In 15 critically ill 
patients (median age 5.3 years; interquartile range 1.2-6.5) who were food tolerant, it revealed 
a median 1.5 (interquartile range 0.7-2.2) ratio of time to reach paracetamol peak to the 
maximum paracetamol concentration (Tmax/Cmax) [49]. In 7 adolescents (mean age 16.4 
years; SD 0.7 years; range 15.5-17.5) it revealed a paracetamol absorption ratio of 1.4 for 
high fat meals and 0.5 for low fat meals [50]. The evidence of these two studies is too limited 
to conclude on age-related changes. 
However, population pharmacokinetic analysis applied in another study yielded a 
significantly lower oral paracetamol absorption rate in the first days of life before stabilizing 
after one week [51]. The lag time reflects the time to reach and permeate the absorbing 
surface of the intestine [2]. Considering that a lag time was observed after oral paracetamol 
administration only and not after rectal administration, it suggests that gastric emptying may 
be the primary determinant of a lag time for oral absorption of paracetamol.  
 
2.2.2.  Antroduodenal contractions 
Antroduodenal motor activity plays a role in the gastric emptying next to fundic contraction, 
pyloric sphincter relaxation and intestinal motor activity. It can be determined by 
antroduodenal manometry which measures intraluminal pressures of the distal stomach and 
the proximal small bowel.   
Fasting antral motor activity and antral motor activity in response to intraduodenal feeding 
did not significantly differ between term and preterm infants [52]. In contrast, the proportion 
of antral clusters temporally associated with duodenal activity in preterm infants was 
significantly lower than that in term infants. Moreover, the degree of association of antral and 
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duodenal activity increased significantly with gestational age [53]. In preterm infants 29 to 32 
weeks of gestational age, the frequency of contractions, the number of contractions per burst, 
and the intraluminal peak pressure of duodenal motility during contractions all increased with 
postgestational age, resulting in a more efficient motility [54]. Similarly Bisset et al reported 
that both the magnitude and organization of motor activity increased with increasing 
gestational age [55]. Berseth et al reported shorter lasting individual duodenal cluster activity 
during fasting periods in preterm than in term infants, but duodenal motor activity in response 
to feeding increased similarly in both groups [52]. The timing of introducing food seems to 
influence the preterm neonates’ (28-32 weeks of gestational age) duodenal motor activity; 
introducing formula early (day 3-5 postnatally) resulted in more mature motor complexes than 
introducing formula late (day 10-14 postnatally) [56]. Preterm infants showed more immature 
duodenal motor activity response to bolus feeding then did term infants [57].   
In conclusion, proximal intestinal (duodenal) motor activity in contrast to antral motor 
activity matures throughout the first weeks of life, with increasing frequency, amplitude, and 
duration of propagating contractions. Regrettable there are no such studies in healthy children 
beyond the newborn period.  
 
2.2.3. Intestinal transit time 
Overall, gastrointestinal motility can be expressed as orocecal transit time (OCTT). This can 
be measured by different techniques: hydrogen breath test, 13C Ureide breath test, 
radiotransmitting capsule, red carmine marker test or scintigraphy. Most common is the 
hydrogen breath test with lactulose as nonabsorbable carbohydrate substrate.  This breath test 
has limited use in the general population, which may include hydrogen-non-responders. Also, 
lactulose may accelerate transit time by its osmotic laxative effect. Accordingly, Vajro et al 
reported in 11 control patients that the mean OCTT after a meal was significantly longer than 
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that after lactulose [58]. Although this method can be used to compare groups in standardized 
studies, it is merely an approach to the physiological situation of intestinal motility.  
We identified four studies using the hydrogen breath test to measure OCTT in different 
pediatric age groups [58-62]. The populations were quite heterogeneous, but there does not 
appear to be an age-related difference in OCTT. In the whole age range from 1 to 17 years the 
mean OCTT was roughly between 60 and 110 minutes, as in adults [62].  The mean OCTT 
measured by the lactose-13C-ureide breath test was 255 minutes (range 165-390) in children 
from 3 to 17 years of age [59]. This method cannot be used in infants below 6 months of age 
as they lack the intestinal bacterial enzymatic activity. In adults the latter test was validated in 
respect to scintigraphy [63]. The lactulose-H2 breath test yielded a significant shorter OCTT 
than did the labeled ureide test, which may be due to the effect of lactulose [64]. Fallingborg 
et al distinguished small intestinal and colonic transit times with the use of a radiotransmitting 
capsule in a small population of 12 healthy children (8 to 14 years) [65]. Small intestinal 
transit time was 7.5 hours and colonic transit time was 17.2 hours. Interestingly, from the 
number of observations in each segment they estimated that the capsule resided in the 
duodenum for 8% of the small intestinal passage; in the proximal part of the small intestines 
for 5%; in the mid part for 12% and in the distal part for 75%. The small intestinal transit time 
of 7.1 hours is considerably longer than that established by the breath tests. The fact that the 
capsule, which was larger than 2 mm, was located in the distal part of the terminal ileum for 
75% of the small intestinal transit time suggests a longer ileo-cecal transit for large particles. 
By means of scintigraphy Bodé et al measured a mean OCTT of 3.1 hours (range 1.3-6.1 
hours) in nine premature infants (mean gestational age 28.9 weeks) [40]. 
 
2.3.  Bile acids 
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Bile is a complex secretory product produced by the liver. It eliminates waste products from 
the body and it promotes digestion and absorption of lipids by the intestines. In preterm 
neonates  the concentration of the bile acids was found to be 4.55 mmol/l in the first few 
weeks postnatally [66]. In 65 healthy preterm newborns the total bile acid concentration was 
consistently higher in those fed with human milk in comparison with those fed with formula. 
Concentrations did not significantly increase over a 3 week follow-up period [67]. 
Concentration did not differ between small and appropriate for gestational age premature 
infants [66]. Challacombe et al compared three age groups, i.e. 2 days postnatal (n=12), 2 to 7 
days (n=8), and 10 days to 7 months (n=14). Gestational ages were not documented. The total 
bile acid concentration in the oldest group was much higher than that in both other groups, 
and at a value comparable to those in adults [68].  
Changes in biliary function can influence solubilisation and consequently absorption of 
lipophilic drugs [3]. 
 
2.4. Pancreatic function 
The exocrine pancreas is a specialized secretory gland, which secretes juice rich in HCO3- 
and digestive enzymes that neutralizes the acidic gastric contents and help digest food. 
Functioning of the exocrine pancreas is typically measured by the fecal Elastase-1(E-1) 
concentration. The E-1 enzyme is highly specific for the pancreas and is not degraded during 
the intestinal passage. Age-related differences in E-1 concentrations were absent in a large 
cohort of healthy subjects (mean age 11.2 years (SD 0.5); age range 2 months to 52 years) 
[69]. Even as many as 96.8% of preterm and term infants up to the age of 12 months without 
known bowel or pancreatic disorders had adult E-1 values after 2 weeks of life, independent 
of gestational age [70]. However, up to 48 hours after birth none of the preterm infants had a 
fecal E-1 concentration of greater than 30 microgram/gram meconium, whereas 43% of the 
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term infants had normal adult values. This discrepancy may be due to either immaturity or 
insufficiency of the exocrine pancreatic function in premature neonates. However, the small 
sample size did not allow differentiating between these two possible causes. Deficient 
exocrine pancreas function as seen in cystic fibrosis patients was associated with lower oral 
bioavailability of mycophenolate mofetil [71]. This suggests an effect on oral drug absorption 
in neonates with immature pancreas function, but this has not been studied to date to our 
knowledge. 
 
2.5.  Intestinal pH 
In comparison with gastric pH, remarkably little is known about the intestinal pH in children. 
Fallingborg et al measured gastrointestinal pH with a radiotransmitting pH-sensitive capsule 
in twelve healthy children aged 8-14 years. The mean value of pH rose from 1.5 in the 
stomach to 6.4 in the duodenum; in the distal part of the small intestine it reached an alkaline 
peak value of 7.4. The pH profile was almost identical to that in healthy adults. A broad 
conclusion on the development of the intestinal pH cannot be drawn as his small population 
consisted merely of older children. It would be worthwhile to repeat the experiment in other 
age groups [65]. 
 
2.6. Intestinal drug metabolism  
Many developmental changes in hepatic drug metabolism and renal clearance have been well 
documented. Data on the ontogeny of intestinal metabolism remain scarce. What is known is 
that enzymes of the cytochrome P450, especially the 3A (CYP3A) subfamily are abundant in 
liver and gut and contribute to the first-pass metabolism of many orally administered drugs in 
adults [72]. Hepatic CYP3A forms present a developmental expression in fetal and pediatric 
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samples; CYP3A4 and CYP3A7 expression levels show to be age-dependent with 
respectively increasing and decreasing levels of total CYP3A expression levels [73]. 
CYP3A ontogeny can be reported as changes in mRNA, protein or activity level. We 
identified two in vitro studies on CYP3A ontogeny in the intestine. One studied fifty-nine 
histologically normal duodenal biopsies from children aged 1 month to 17 years for CYP3A 
mRNA by quantification and CYP3A proteins localization by immunohistochemistry [74]. 
The other studied duodenal biopsies and surgical sections from 104 children aged 2 weeks to 
17 years and 11 foetuses for CYP3A protein expression by immunohistochemistry and 
activity by the formation of 6beta-hydroxytestosterone from testosterone [75]. CYP3A4 and 
CYP3A5 mRNA expression levels were to decrease with age. Showing expression levels 
were high in the first year of life and decreased thereafter [74]. This is in contrast with protein 
expression levels reported in the second study showing CYP3A protein expression 
significantly increased with age [75]. The discrepancy of decreasing mRNA expression and 
increasing protein levels with age might reflect a posttranscriptional regulatory mechanism 
that is not elucidated to date according to the authors [74]. Dissociation between protein and 
mRNA levels during the maturation process was already reported for CYP2D6 liver enzymes 
[76]. The location of the CYP3A protein in enterocytes assumes a maturation profile occurs. 
In the duodenal biopsies of children less than 6 months of age, CYP3A protein was detected 
in only half of the enterocytes, in the older children, however, CYP3A protein was expressed 
in all cells [74]. Moreover, the increase in CYP3A protein levels with age is mirrored with 
increasing CYP3A4 activity. It changes from undetectable in fetal samples, low in neonates 
and adult levels in children older than 5 years of age, as reflected by 6beta-
hydroxytestosterone formation [75].  
Intestinal CYP3A4, CYP3A5 mRNA levels have been established in pediatric liver recipients 
(age 0.1-15 years) at the time of transplant surgery [77]. Unfortunately the authors did not 
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study the effect of age within their cohort. Adult data show similar CYP3A4 and CYP3A5 
expression levels [78]. This suggests that intestinal CYP3A expression does not change 
beyond childhood. However, because the range of levels reported in children was very wide, 
age-related changes from 0.1 year of age onwards can not be excluded [78]. Intestinal 
CYP3A5 mRNA levels were significantly higher in CYP3A5*1 gene carriers (expressors) 
than CYP3A5*3 homozygous patients (non-expressors) and observed in both the children and 
adult study. In CYP3A5*1 carriers, CYP3A5 mRNA accounted for 20-30% of all CYP3A 
mRNA detected [77-78]. 
In vivo studies on oral bioavailability of CYP3A substrates in relation to age are scarce. Our 
own research showed that median midazolam oral bioavailability in preterm infants (28-32 
weeks, <10 days of age) is significantly higher than in adults (50% vs. 30%) [79-81]. This 
likely reflects developmentally low intestinal and hepatic CYP3A activity, as midazolam is a 
validated probe drug for CYP3A4/5 activity.  
Interestingly, the type of feeding (breast milk or formula) seems to impact the developmental 
pattern of combined intestinal and hepatic CYP3A in neonates. In children who received oral 
dextromethorphan six times between two weeks and 6 months of age, the urinary 
metabolite/dextromethorphan ratio as a measure of CYP3A4 activity clearly increased over 
this period. Moreover, this increase was faster for formula vs. breastmilk fed children [82]. 
This finding suggests a differential effect of components of these milk formulations on the 
induction of intestinal and hepatic CYP3A activity in the first months of life. 
The ontogeny of other drug metabolizing enzymes in the intestine remains to be elucidated. 
 
2.7. Intestinal drug transporter  
Multidrug resistance protein 1 (MDR1/P-glycoprotein) is a plasma membrane glycoprotein 
acting as an efflux system. Based on in vitro studies it is currently considered the most 
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prominent gut transporter [83]. It is located in many tissues and specifically within the brush 
border in the small intestine. Its expression is genetically controlled by the ABCB1 gene [84]. 
MDR1 action in the enterocyte reduces the bioavailability of orally administered drugs as 
these are expelled into the intestinal lumen. MDR1 protein can be localized by 
immunohistochemistry and mRNA quantification in intestinal tissue. In the earlier mentioned 
study evaluating 59 duodenal biopsies of children aged from 1 month to 17 year, MDR1 
mRNA expression was highly variable and not related to age [74]. MDR1 protein was 
detected in all the enterocytes and was located on the apical surface. In the biopsies in 
children younger than 3 years, additional staining was located on a limited upper part of the 
lateral surface.  
A possible age effect in relation to of the ABCB1 genotype was found for oral bioavailability 
of the MDR1 substrate cyclosporine. 104 children with renal disease (age 0.36-16.3 years) 
were grouped by age and genotyped for ABCB1 gene. The pre-hepatic extraction ratio of 
cyclosporine was ABCB1 genotype dependent only in children older than 8 years, resulting in 
corresponding differences in oral bioavailability. No such association was found in younger 
patients, which suggests an interaction of age and genotype on MDR1 activity [85]. 
In the context of the previously mentioned study in pediatric liver recipients, MDR1 mRNA 
was determined as well and results were similar as for CYP3A, i.e. the median MDR1 mRNA 
expression did not differ between children and adults, but widely ranged in the pediatric 
population [77-78]. 
 Interestingly, in noninflamed duodenal biopsies of children with Crohn’s disease, MDR1 
mRNA expression was significantly higher than that in normal biopsies. Expression of MDR1 
was highly variable in both groups [86]. The effect of age was not examined in this study. The 
higher levels of MDR1 expression could have been induced by systemic inflammation present 
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in Crohn’s disease, which is likely to lead to an elevated first pass metabolism of xenobiotics 
used in the treatment.   
To our knowledge the intestinal ontogeny of other members of the ATP binding cassette 
transporters, such as multidrug resistance protein 2 (MRP2/ABCC2) or breast cancer 
resistance protein (BCRP/ABCG2), has not been studied to date [83, 87-89].   
 
3. Conclusion  
 
This literature review makes clear that GI processes that govern drug absorption change from 
the neonatal period up to adulthood. Consequently these changes could have an impact on 
drug absorption depending on the drug characteristics [3-4]. The review also brought to light 
important knowledge gaps regarding these processes and especially their impact on drug 
absorption. 
Key findings in the research done so far are the following. Apart from a brief peak postnatally 
the gastric pH is about 2-3 in children of all ages. Postprandial its rise is due to the buffering 
effect of milk-based feeding. Especially in frequently fed neonates the pH may therefore be 
higher for a longer period during a 24 hour period, then in older children who eat less 
frequently. Gastric emptying time reported in the literature is highly variable. Standard gastric 
emptying tests do not reveal evident age-related changes. Population pharmacokinetic 
analysis shows a markedly paracetamol absorption decrease in the first few days of life, 
which suggests delayed gastric emptying. This delay could perhaps be explained by 
maturation of antroduodenal contractions. 
There are no studies done examining antroduodenal contractions beyond the neonatal period. 
Intestinal transit time (in terms of mean OCTT) does not appear to be subject to age-related 
changes; it is roughly between 60 and 110 minutes in the age range of 1 to 17 years, as 
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measured by hydrogen breath test. The one study that used a capsule to measure OCTT 
showed a much longer transit time than any of the other studies using the lactulose breath test. 
This finding suggests that this latter test cannot be used to determine an absolute OCTT. It 
probably rather measures intra-individual changes in OCTT or differences between cohorts. A 
developmental change in biliary function appears to be present, with bile acids concentration 
reaching adult values around the age of four years. Pancreatic function appears to be sufficient 
in the large majority of healthy newborns, independent of gestational age. Intestinal pH has 
only been studied in a cohort of older children. Adult values were found in this cohort; 
therefore possible age-related changes remain to be elucidated. For a large proportion of drugs 
there seems to be a developmental pattern in CYP3A, which is the most important drug 
metabolizing enzyme in the intestines. CYP3A protein and activity levels were found to 
increase with age. These in vitro data are in line with higher oral bioavailability of midazolam 
in premature children compared to adults. Evidence on possible age-related effect on MDR-1 
activity is contradictory and not elusive yet. 
 
4.   Expert Opinion  
 
4.1  Information gaps  
In summary, the main information gaps on the ontogeny of GI processes governing oral drug 
absorption have not yet been bridged. We need more knowledge on intestinal transit time, 
intestinal pH and the ontogeny of intestinal drug metabolizing enzymes and drug transporter 
proteins. The ultimate goal of research efforts in this field should be to predict more precisely 
the oral disposition of drugs in children across the pediatric age range. Below we describe 
some research approaches, both in vitro and in vivo, which are promising for future research 
to provide a better understanding of oral drug absorption in children.  
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4.1 In vitro drug dissolution/solubility model (TIM) 
The Dutch Institute of Innovative Research has developed the TNO Gastro-Intestinal Tract 
model (TIM), a computer controlled dynamic system which mimics the physiological human 
conditions in stomach and intestines [90-91]. Parameters such as pH, temperature, peristaltic 
movements, transit time, secretion of digestion enzymes, bile and pancreatic juices can be 
adjusted. Intraluminal processing of drug dosage forms, including transit, release and 
dissolution can be simulated [92]. Removal of dissolved drug molecules from the intestinal 
compartments allows assessing the fraction of drug potentially available for small intestinal 
absorption [91]. This model has been extensively validated to simulate these processes in 
adults. It appears an interesting approach to test oral drug absorption in conditions with 
typical age-related physiological characteristics. Especially, the additional impact of existing 
oral formulations frequently given to children can be studied. It may also help to study the 
effect of drug manipulations to enhance drug ingestion by children (e.g. dissolving tablets in 
apple juice, apple sauce, ‘hiding’ in regular food, crushing, et cetera). Representative drugs of 
the different BCS classes can also be studied systematically for dissolution and solubility.  
 
4.2  In vitro drug metabolism and transporter studies 
The extensive studies on in vitro hepatic drug metabolism, for example by the group of Hines 
and colleagues could serve as an example [93]. Similarly, the ontogeny of drug metabolizing 
enzymes and transporters should be studied in intestinal samples from the different parts of 
the intestine and from children across the pediatric age span. New methods are quickly 
becoming available, not only to study drug transporter expression (mRNA) but also protein 
content, using sensitive LC-MS-MS methods.  
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4.3  Modeling and simulation: PB-PK models and population PK 
The available data on age-related changes in relevant GI processes as well as possibly those 
from the TIM simulations can be incorporated in population based pharmacokinetics (PB-PK) 
software programs such as Simcyp®, PKsim® or GastroPlus®. These programs can then 
simulate fate of drugs given to children of different ages and provide guidance for age-
appropriate dosing.  
At this time, the usefulness of these programs is still hampered by the relative lack of 
physiological data across all age groups. Moreover, validation of the model is also still limited 
as we have little pharmacokinetic data to validate the model in especially the neonatal and 
infant age groups are scarce [94]. It is to be expected that increasing use of these programs 
will generate sufficient data to further validate the models.  
 
4.4  Mechanism-based approach for in vivo studies 
Another approach to learn more about the ontogeny of specific (intestinal) drug metabolizing 
enzyme and/or transporter pathways is a mechanism-based one [95]. The pharmacokinetics of 
drugs that represent a single pathway, studied in children of all ages, may provide valuable 
information on the ontogeny of that specific pathway. For example, determination of the 
plasma clearance of midazolam is a validated and widely used method to study interindividual 
variation in CYP3A activity in both adults and children [96]. 
To elucidate age-related changes in intestinal enzymes/transporters, independent of hepatic 
activity, we will need both oral and intravenous pharmacokinetic data, preferably from the 
same patients. At this time these data are scarce in children, even for CYP3A/midazolam. Full 
PK studies to determine bioavailability for a probe drug using a multi-day cross-over design 
are hardly feasible in children for ethical and practical reasons. As a major reason, children 
will not benefit from the drug but rather will experience the drug effect and risk adverse 
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events and have significant burden. Alternatively a stable-labeled isotope or a (very weak) 
radioactive-labeled microdose can be used [97-98]. In both a labeled probe drug is added to 
an intravenous therapeutic dose. Parent compound and metabolites can therefore be traced in 
serum and urine. This enables simultaneous determination of the pharmacokinetics of 
therapeutic IV and the labeled oral dose. It eliminates the risk of therapeutic effect/toxicity as 
the child already receives the drug for clinical reasons. A prerequisite for the use of 
microdosing in this context is that dose-linearity exists across the dosing range. For a number 
of drugs dose-linearity for microdosing has been established, whereas others clearly do not 
qualify [99-100].  
Microdosing is a relatively novel technique used in adults. The microdose (one-hundredth of 
the predicted pharmacologic dose or 100 micrograms) contains a natural occurring radioactive 
carbon label (carbon 14, 14C) which can be detected with highly sensitive methods as 
accelerator mass spectometry (AMS) [99]. Developmental changes in intestinal drug 
metabolizing enzymes can be delineated by investigating multiple age groups. Microdosing 
has been used once in preterm infants in a small pharmacokinetic study of ursodiol in the 
United States [101]. 
23 
 
References 
 
1. Schirm E, Tobi H, de Vries TW, Choonara I, De Jong-van den Berg LT. Lack of 
appropriate formulations of medicines for children in the community. Acta Paediatr 2003 
Dec;92(12):1486-9. 
2. Atkinson AJ, Abernethy DR, Daniels CE, Dedrick RL, Martkey SP. Drug Absorption 
and Bioavailability.  Principles of Clinical Pharmacology. 2nd ed: Academic Press 2007:37-
58. 
3. Martinez MN, Amidon GL. A mechanistic approach to understanding the factors 
affecting drug absorption: a review of fundamentals. J Clin Pharmacol 2002 Jun;42(6):620-
43. 
4. Kearns GL, Abdel-Rahman SM, Alander SW, Blowey DL, Leeder JS, Kauffman RE. 
Developmental pharmacology--drug disposition, action, and therapy in infants and children. 
N Engl J Med 2003 Sep 18;349(12):1157-67. 
5. Jacqz-Aigrain E. Drug policy in Europe Research and funding in neonates: current 
challenges, future perspectives, new opportunities. Early Hum Dev 2011 Mar;87 Suppl 1:S27-
30. 
6. FDA. U.S. Food and Drug Administration.   [cited; Available from: 
http://www.fda.gov/ScienceResearch/SpecialTopics/PediatricTherapeuticsResearch/default.ht
m 
7. Hines RN, McCarver DG. The ontogeny of human drug-metabolizing enzymes: phase 
I oxidative enzymes. J Pharmacol Exp Ther 2002 Feb;300(2):355-60. 
8. Smits A, Kulo A, de Hoon JN, Allegaert K. Pharmacokinetics of Drugs in Neonates: 
Pattern Recognition Beyond Compound Specific Observations. Curr Pharm Des 2012 Feb 27. 
24 
 
9. Strolin Benedetti M, Whomsley R, Baltes EL. Differences in absorption, distribution, 
metabolism and excretion of xenobiotics between the paediatric and adult populations. Expert 
Opin Drug Metab Toxicol 2005 Oct;1(3):447-71. 
10. Yokoi T. Essentials for starting a pediatric clinical study (1): Pharmacokinetics in 
children. J Toxicol Sci 2009;34 Suppl 2:SP307-12. 
11. Bowles A, Keane J, Ernest T, Clapham D, Tuleu C. Specific aspects of gastro-
intestinal transit in children for drug delivery design. Int J Pharm 2010 Aug 16;395(1-2):37-
43. 
12. Cote CJ, Goudsouzian NG, Liu LM, Dedrick DF, Szyfelbein SK. Assessment of risk 
factors related to the acid aspiration syndrome in pediatric patients-gastric ph and residual 
volume. Anesthesiology 1982 Jan;56(1):70-2. 
13. Datta S, Houle GL, Fox GS. Concentration of lidocaine hydrochloride in newborn 
gastric fluid after elective caesarean section and vaginal delivery with epidural analgesia. Can 
Anaesth Soc J 1975 Jan;22(1):79-83. 
14. Goresky GV, Finley GA, Bissonnette B, Shaffer EA. Efficacy, duration, and 
absorption of a paediatric oral liquid preparation of ranitidine hydrochloride. Can J Anaesth 
1992 Oct;39(8):791-8. 
15. Jahr JS, Burckart G, Smith SS, Shapiro J, Cook DR. Effects of famotidine on gastric 
pH and residual volume in pediatric surgery. Acta Anaesthesiol Scand 1991 Jul;35(5):457-60. 
16. Kelly EJ, Chatfield SL, Brownlee KG, Ng PC, Newell SJ, Dear PR, et al. The effect of 
intravenous ranitidine on the intragastric pH of preterm infants receiving dexamethasone. 
Arch Dis Child 1993 Jul;69(1 Spec No):37-9. 
17. Kelly EJ, Newell SJ, Brownlee KG, Primrose JN, Dear PR. Gastric acid secretion in 
preterm infants. Early Hum Dev 1993 Dec 31;35(3):215-20. 
25 
 
18. Kraus G, Krishna DR, Chmelarsch D, Schmid M, Klotz U. Famotidine. 
Pharmacokinetic properties and suppression of acid secretion in paediatric patients following 
cardiac surgery. Clin Pharmacokinet 1990 Jan;18(1):77-81. 
19. Maekawa N, Mikawa K, Yaku H, Nishina K, Obara H. Effects of 2-, 4- and 12-hour 
fasting intervals on preoperative gastric fluid pH and volume, and plasma glucose and lipid 
homeostasis in children. Acta Anaesthesiol Scand 1993 Nov;37(8):783-7. 
20. Miller BR, Tharp JA, Issacs WB. Gastric residual volume in infants and children 
following a 3-hour fast. J Clin Anesth 1990 Sep-Oct;2(5):301-5. 
21. Nishina K, Mikawa K, Maekawa N, Tamada M, Obara H. Omeprazole reduces 
preoperative gastric fluid acidity and volume in children. Can J Anaesth 1994 
Oct;41(10):925-9. 
22. Oderda G, Rapa A, Chiorboli E, Ronchi B, Zavallone A, Strigini L. Measurement of 
postprandial changes in urine acid output to detect changes of gastric acid secretion after 
proton pump inhibitors in children. Dig Dis Sci 2002 Aug;47(8):1843-9. 
23. Omari TI, Davidson GP. Multipoint measurement of intragastric pH in healthy 
preterm infants. Arch Dis Child Fetal Neonatal Ed 2003 Nov;88(6):F517-20. 
24. Rogers IM, Drainer IK, Moore MR, Buchanan KD. Plasma gastrin in congenitial 
hypertrophic pyloric stenosis. A hypothesis disproved. Arch Dis Child 1975 Jun;50(6):467-
71. 
25. Smith LJ, Kaminsky S, D'Souza SW. Neonatal fat digestion and lingual lipase. Acta 
Paediatr Scand 1986 Nov;75(6):913-8. 
26. Splinter WM, Schaefer JD. Unlimited clear fluid ingestion two hours before surgery in 
children does not affect volume or pH of stomach contents. Anaesth Intensive Care 1990 
Nov;18(4):522-6. 
26 
 
27. Splinter WM, Stewart JA, Muir JG. Large volumes of apple juice preoperatively do 
not affect gastric pH and volume in children. Can J Anaesth 1990 Jan;37(1):36-9. 
28. Whetstine LJ, Hulsey TC, Annibale DJ, Pittard WB. Supplemental oxygen and gastric 
pH in unfed preterm infants. South Med J 1995 Apr;88(4):458-61. 
29. Yildiz F, Tryba M, Kuehn K, Hausdoerfer J. Reduction of gastric acid secretion. The 
efficacy of pre-anaesthetic oral cimetidine in children. Anaesthesia 1984 Apr;39(4):314-8. 
30. Miller RA. Observations on the gastric acidity during the first month of life. Arch Dis 
Child 1941 Mar;16(85):22-30. 
31. Lopez-Alonso M, Moya MJ, Cabo JA, Ribas J, del Carmen Macias M, Silny J, et al. 
Twenty-four-hour esophageal impedance-pH monitoring in healthy preterm neonates: rate 
and characteristics of acid, weakly acidic, and weakly alkaline gastroesophageal reflux. 
Pediatrics 2006 Aug;118(2):e299-308. 
32. Omari TI, Haslam RR, Lundborg P, Davidson GP. Effect of omeprazole on acid 
gastroesophageal reflux and gastric acidity in preterm infants with pathological acid reflux. J 
Pediatr Gastroenterol Nutr 2007 Jan;44(1):41-4. 
33. Demir H, Ozen H, Kocak N, Saltik-Temizel IN, Gurakan F. Does simultaneous gastric 
and esophageal pH monitoring increase the diagnosis of gastroesophageal reflux disease? 
Turk J Pediatr 2005 Jan-Mar;47(1):14-6. 
34. Kleinman RE, Goulet OJ, Mieli-Vergani G, Sanderson IR, Sherman PM, Shneider BL. 
Walker's Pediatric Gastrointestinal Disease. Shelton, CT: People's Medical Publishing House, 
2008. 
35. Boyle JT. Acid secretion from birth to adulthood. J Pediatr Gastroenterol Nutr 2003 
Nov-Dec;37 Suppl 1:S12-6. 
27 
 
36. Huang NN, High RH. Comparison of serum levels following the administration of oral 
and parenteral preparations of penicillin to infants and children of various age groups. J 
Pediatr 1953 Jun;42(6):657-8. 
37. Hoekstra JH, van den Aker JH, Kneepkens CM, Stellaard F, Geypens B, Ghoos YF. 
Evaluation of 13CO2 breath tests for the detection of fructose malabsorption. J Lab Clin Med 
1996 Mar;127(3):303-9. 
38. Perri F, Pastore M, Zicolella A, Annese V, Quitadamo M, Andriulli A. Gastric 
emptying of solids is delayed in celiac disease and normalizes after gluten withdrawal. Acta 
Paediatr 2000 Aug;89(8):921-5. 
39. Hoffman I, Tertychnyy A, Ectors N, De Greef T, Haesendonck N, Tack J. 
Duodenogastro-esophageal reflux in children with refractory gastro-esophageal reflux disease. 
J Pediatr 2007 Sep;151(3):307-11. 
40. Bode S, Dreyer M, Greisen G. Gastric emptying and small intestinal transit time in 
preterm infants: a scintigraphic method. J Pediatr Gastroenterol Nutr 2004 Oct;39(4):378-82. 
41. Di Lorenzo C, Piepsz A, Ham H, Cadranel S. Gastric emptying with gastro-
oesophageal reflux. Arch Dis Child 1987 May;62(5):449-53. 
42. Seibert JJ, Byrne WJ, Euler AR. Gastric emptying in children: unusual patterns 
detected by scintigraphy. AJR Am J Roentgenol 1983 Jul;141(1):49-51. 
43. Cucchiara S, Bortolotti M, Colombo C, Boccieri A, De Stefano M, Vitiello G, et al. 
Abnormalities of gastrointestinal motility in children with nonulcer dyspepsia and in children 
with gastroesophageal reflux disease. Dig Dis Sci 1991 Aug;36(8):1066-73. 
44. Miele E, Tozzi A, Staiano A, Toraldo C, Esposito C, Clouse RE. Persistence of 
abnormal gastrointestinal motility after operation for Hirschsprung's disease. Am J 
Gastroenterol 2000 May;95(5):1226-30. 
28 
 
45. Yahav J, Avigad S, Frand M, Shem-Tov A, Barzilay Z, Linn S, et al. Assessment of 
intestinal and cardiorespiratory function in children with congenital heart disease on high-
caloric formulas. J Pediatr Gastroenterol Nutr 1985 Oct;4(5):778-85. 
46. Demirbilek S, Karaman A, Gurunluoglu K, Akin M, Tas E, Aksoy RT, et al. Delayed 
gastric emptying in gastroesophageal reflux disease: the role of malrotation. Pediatr Surg Int 
2005 Jun;21(6):423-7. 
47. Graff J, Brinch K, Madsen JL. Simplified scintigraphic methods for measuring 
gastrointestinal transit times. Clin Physiol 2000 Jul;20(4):262-6. 
48. Bennink R, Peeters M, Van den Maegdenbergh V, Geypens B, Rutgeerts P, De Roo 
M, et al. Evaluation of small-bowel transit for solid and liquid test meal in healthy men and 
women. Eur J Nucl Med 1999 Dec;26(12):1560-6. 
49. Mayer AP, Durward A, Turner C, Skellett S, Dalton N, Tibby SM, et al. Amylin is 
associated with delayed gastric emptying in critically ill children. Intensive Care Med 2002 
Mar;28(3):336-40. 
50. Lodefalk M, Aman J, Bang P. Effects of fat supplementation on glycaemic response 
and gastric emptying in adolescents with Type 1 diabetes. Diabet Med 2008 Sep;25(9):1030-
5. 
51. Anderson BJ, van Lingen RA, Hansen TG, Lin YC, Holford NH. Acetaminophen 
developmental pharmacokinetics in premature neonates and infants: a pooled population 
analysis. Anesthesiology 2002 Jun;96(6):1336-45. 
52. Berseth CL, Ittmann PI. Antral and duodenal motor responses to duodenal feeding in 
preterm and term infants. J Pediatr Gastroenterol Nutr 1992 Feb;14(2):182-6. 
53. Ittmann PI, Amarnath R, Berseth CL. Maturation of antroduodenal motor activity in 
preterm and term infants. Dig Dis Sci 1992 Jan;37(1):14-9. 
29 
 
54. Morriss FH, Jr., Moore M, Weisbrodt NW, West MS. Ontogenic development of 
gastrointestinal motility: IV. Duodenal contractions in preterm infants. Pediatrics 1986 
Dec;78(6):1106-13. 
55. Bisset WM, Watt JB, Rivers RP, Milla PJ. Measurement of small-intestinal motor 
activity in the preterm infant. J Biomed Eng 1988 Apr;10(2):155-8. 
56. Berseth CL, Nordyke CK, Valdes MG, Furlow BL, Go VL. Responses of 
gastrointestinal peptides and motor activity to milk and water feedings in preterm and term 
infants. Pediatr Res 1992 Jun;31(6):587-90. 
57. al Tawil Y, Berseth CL. Gestational and postnatal maturation of duodenal motor 
responses to intragastric feeding. J Pediatr 1996 Sep;129(3):374-81. 
58. Vajro P, Silano G, Longo D, Staiano A, Fontanella A. Orocoecal transit time in 
healthy and constipated children. Acta Paediatr Scand 1988 Jul;77(4):583-6. 
59. Van Den Driessche M, Van Malderen N, Geypens B, Ghoos Y, Veereman-Wauters G. 
Lactose-[13C]ureide breath test: a new, noninvasive technique to determine orocecal transit 
time in children. J Pediatr Gastroenterol Nutr 2000 Oct;31(4):433-8. 
60. Khin M, Bolin TD, Tin O, Thein Win N, Kyaw-Hla S, Thein Thein M. Investigation 
of small-intestinal transit time in normal and malnourished children. J Gastroenterol 1999 
Dec;34(6):675-9. 
61. Murphy MS, Nelson R, Eastham EJ. Measurement of small intestinal transit time in 
children. Acta Paediatr Scand 1988 Nov;77(6):802-6. 
62. Vreugdenhil G, Sinaasappel M, Bouquet J. A comparative study of the mouth to 
caecum transit time in children and adults using a weight adapted lactulose dose. Acta 
Paediatr Scand 1986 May;75(3):483-8. 
30 
 
63. Geypens B, Bennink R, Peeters M, Evenepoel P, Mortelmans L, Maes B, et al. 
Validation of the lactose-[13C]ureide breath test for determination of orocecal transit time by 
scintigraphy. J Nucl Med 1999 Sep;40(9):1451-5. 
64. Wutzke KD, Heine WE, Plath C, Leitzmann P, Radke M, Mohr C, et al. Evaluation of 
oro-coecal transit time: a comparison of the lactose-[13C, 15N]ureide 13CO2- and the 
lactulose H2-breath test in humans. Eur J Clin Nutr 1997 Jan;51(1):11-9. 
65. Fallingborg J, Christensen LA, Ingeman-Nielsen M, Jacobsen BA, Abildgaard K, 
Rasmussen HH, et al. Measurement of gastrointestinal pH and regional transit times in normal 
children. J Pediatr Gastroenterol Nutr 1990 Aug;11(2):211-4. 
66. Boehm G, Bierbach U, Senger H, Jakobsson I, Minoli I, Moro G, et al. Activities of 
lipase and trypsin in duodenal juice of infants small for gestational age. J Pediatr 
Gastroenterol Nutr 1991 Apr;12(3):324-7. 
67. Jarvenpaa AL, Rassin DK, Kuitunen P, Gaull GE, Raiha NC. Feeding the low-birth-
weight infant. III. Diet influences bile acid metabolism. Pediatrics 1983 Nov;72(5):677-83. 
68. Challacombe DN, Edkins S, Brown GA. Duodenal bile acids in infancy. Arch Dis 
Child 1975 Nov;50(11):837-43. 
69. Walkowiak J, Herzig KH, Strzykala K, Przyslawski J, Krawczynski M. Fecal elastase-
1 is superior to fecal chymotrypsin in the assessment of pancreatic involvement in cystic 
fibrosis. Pediatrics 2002 Jul;110(1 Pt 1):e7. 
70. Nissler K, Von Katte I, Huebner A, Henker J. Pancreatic elastase 1 in feces of preterm 
and term infants. J Pediatr Gastroenterol Nutr 2001 Jul;33(1):28-31. 
71. de Winter BC, Monchaud C, Premaud A, Pison C, Kessler R, Reynaud-Gaubert M, et 
al. Bayesian estimation of mycophenolate mofetil in lung transplantation, using a population 
pharmacokinetic model developed in kidney and lung transplant recipients. Clin 
Pharmacokinet 2012 Jan 1;51(1):29-39. 
31 
 
72. Hines RN. The ontogeny of drug metabolism enzymes and implications for adverse 
drug events. Pharmacol Ther 2008 May;118(2):250-67. 
73. Stevens JC, Hines RN, Gu C, Koukouritaki SB, Manro JR, Tandler PJ, et al. 
Developmental expression of the major human hepatic CYP3A enzymes. J Pharmacol Exp 
Ther 2003 Nov;307(2):573-82. 
74. Fakhoury M, Litalien C, Medard Y, Cave H, Ezzahir N, Peuchmaur M, et al. 
Localization and mRNA expression of CYP3A and P-glycoprotein in human duodenum as a 
function of age. Drug Metab Dispos 2005 Nov;33(11):1603-7. 
75. Johnson TN, Tanner MS, Taylor CJ, Tucker GT. Enterocytic CYP3A4 in a paediatric 
population: developmental changes and the effect of coeliac disease and cystic fibrosis. Br J 
Clin Pharmacol 2001 May;51(5):451-60. 
76. Treluyer JM, Jacqz-Aigrain E, Alvarez F, Cresteil T. Expression of CYP2D6 in 
developing human liver. Eur J Biochem 1991 Dec 5;202(2):583-8. 
77. Fukudo M, Yano I, Masuda S, Goto M, Uesugi M, Katsura T, et al. Population 
pharmacokinetic and pharmacogenomic analysis of tacrolimus in pediatric living-donor liver 
transplant recipients. Clin Pharmacol Ther 2006 Oct;80(4):331-45. 
78. Fukudo M, Yano I, Yoshimura A, Masuda S, Uesugi M, Hosohata K, et al. Impact of 
MDR1 and CYP3A5 on the oral clearance of tacrolimus and tacrolimus-related renal 
dysfunction in adult living-donor liver transplant patients. Pharmacogenet Genomics 2008 
May;18(5):413-23. 
79. de Wildt SN, Kearns GL, Hop WC, Murry DJ, Abdel-Rahman SM, van den Anker JN. 
Pharmacokinetics and metabolism of oral midazolam in preterm infants. Br J Clin Pharmacol 
2002 Apr;53(4):390-2. 
80. Paine MF, Shen DD, Kunze KL, Perkins JD, Marsh CL, McVicar JP, et al. First-pass 
metabolism of midazolam by the human intestine. Clin Pharmacol Ther 1996 Jul;60(1):14-24. 
32 
 
81. Mandema JW, Tuk B, van Steveninck AL, Breimer DD, Cohen AF, Danhof M. 
Pharmacokinetic-pharmacodynamic modeling of the central nervous system effects of 
midazolam and its main metabolite alpha-hydroxymidazolam in healthy volunteers. Clin 
Pharmacol Ther 1992 Jun;51(6):715-28. 
82. Blake MJ, Abdel-Rahman SM, Pearce RE, Leeder JS, Kearns GL. Effect of diet on the 
development of drug metabolism by cytochrome P-450 enzymes in healthy infants. Pediatr 
Res 2006 Dec;60(6):717-23. 
83. Dietrich CG, Geier A, Oude Elferink RP. ABC of oral bioavailability: transporters as 
gatekeepers in the gut. Gut 2003 Dec;52(12):1788-95. 
84. Cascorbi I. P-glycoprotein: tissue distribution, substrates, and functional consequences 
of genetic variations. Handb Exp Pharmacol 2011(201):261-83. 
85. Fanta S, Niemi M, Jonsson S, Karlsson MO, Holmberg C, Neuvonen PJ, et al. 
Pharmacogenetics of cyclosporine in children suggests an age-dependent influence of ABCB1 
polymorphisms. Pharmacogenet Genomics 2008 Feb;18(2):77-90. 
86. Fakhoury M, Lecordier J, Medard Y, Peuchmaur M, Jacqz-Agrain E. Impact of 
inflammation on the duodenal mRNA expression of CYP3A and P-glycoprotein in children 
with Crohn's disease. Inflamm Bowel Dis 2006 Aug;12(8):745-9. 
87. Zhao W, Fakhoury M, Deschenes G, Roussey G, Brochard K, Niaudet P, et al. 
Population pharmacokinetics and pharmacogenetics of mycophenolic acid following 
administration of mycophenolate mofetil in de novo pediatric renal-transplant patients. J Clin 
Pharmacol 2010 Nov;50(11):1280-91. 
88. Ohmann EL, Burckart GJ, Brooks MM, Chen Y, Pravica V, Girnita DM, et al. Genetic 
polymorphisms influence mycophenolate mofetil-related adverse events in pediatric heart 
transplant patients. J Heart Lung Transplant 2010 May;29(5):509-16. 
33 
 
89. Zhao W, Elie V, Roussey G, Brochard K, Niaudet P, Leroy V, et al. Population 
pharmacokinetics and pharmacogenetics of tacrolimus in de novo pediatric kidney transplant 
recipients. Clin Pharmacol Ther 2009 Dec;86(6):609-18. 
90. Blanquet S, Zeijdner E, Beyssac E, Meunier JP, Denis S, Havenaar R, et al. A 
dynamic artificial gastrointestinal system for studying the behavior of orally administered 
drug dosage forms under various physiological conditions. Pharm Res 2004 Apr;21(4):585-
91. 
91. Brouwers J, Anneveld B, Goudappel GJ, Duchateau G, Annaert P, Augustijns P, et al. 
Food-dependent disintegration of immediate release fosamprenavir tablets: in vitro evaluation 
using magnetic resonance imaging and a dynamic gastrointestinal system. Eur J Pharm 
Biopharm 2011 Feb;77(2):313-9. 
92. Wilding IR, Kenyon CJ, Hooper G. Gastrointestinal spread of oral prolonged-release 
mesalazine microgranules (Pentasa) dosed as either tablets or sachet. Aliment Pharmacol Ther 
2000 Feb;14(2):163-9. 
93. Hines RN. Ontogeny of human hepatic cytochromes P450. J Biochem Mol Toxicol 
2007;21(4):169-75. 
94. Johnson TN, Rostami-Hodjegan A, Tucker GT. Prediction of the clearance of eleven 
drugs and associated variability in neonates, infants and children. Clin Pharmacokinet 
2006;45(9):931-56. 
95. Ince I, de Wildt SN, Tibboel D, Danhof M, Knibbe CA. Tailor-made drug treatment 
for children: creation of an infrastructure for data-sharing and population PK-PD modeling. 
Drug Discov Today 2009 Mar;14(5-6):316-20. 
96. de Wildt SN, Ito S, Koren G. Challenges for drug studies in children: CYP3A 
phenotyping as example. Drug Discov Today 2009 Jan;14(1-2):6-15. 
34 
 
97. Gorski JC, Jones DR, Haehner-Daniels BD, Hamman MA, O'Mara EM, Jr., Hall SD. 
The contribution of intestinal and hepatic CYP3A to the interaction between midazolam and 
clarithromycin. Clin Pharmacol Ther 1998 Aug;64(2):133-43. 
98. Lappin G, Shishikura Y, Jochemsen R, Weaver RJ, Gesson C, Brian Houston J, et al. 
Comparative pharmacokinetics between a microdose and therapeutic dose for clarithromycin, 
sumatriptan, propafenone, paracetamol (acetaminophen), and phenobarbital in human 
volunteers. Eur J Pharm Sci 2011 Jun 14;43(3):141-50. 
99. Lappin G, Garner RC. The utility of microdosing over the past 5 years. Expert Opin 
Drug Metab Toxicol 2008 Dec;4(12):1499-506. 
100. Lappin G, Kuhnz W, Jochemsen R, Kneer J, Chaudhary A, Oosterhuis B, et al. Use of 
microdosing to predict pharmacokinetics at the therapeutic dose: experience with 5 drugs. 
Clin Pharmacol Ther 2006 Sep;80(3):203-15. 
101. Baillie R, Bosley J, Blood A, Vasquez H, Vuong L. Compartmental analysis of 
ursodiol PK neonates using AMS. Clin Pharmacol Ther;Feb 89. 
 
 
35 
 
Figure 1: Gastric pH measured in neonates by 24-h monitoring or gastric aspirates. 
References correspond with references in the text. 
